Biopharm, we will leave all the questions you raise for each entity, and their respective attys, to figure out and negotiate as necessary. On the ???s of patentabilities of subject matters, those are questions best left to respective Attys working with respective patent offices(courts if necessary) to ascertain. Those questions cannot, should not, be attempted to be resolved by us here, simply because we do not have all the facts immediately in front of us.
Market Data 
Markets 
AI
